19:18 , Feb 21, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The pre-HIV infection fraction of CD4+ T cells expressing integrin α4β7 could help predict susceptibility to HIV infection. In 70 of 206 at-risk women from South Africa and Kenya who contracted HIV via...
16:08 , Jun 7, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other An S. typhimurium-based DNA vaccine vector expressing tumor antigens and Bacterial AIDA-I autotransporter (AIDA-I) could be used to deliver cancer vaccines. The vaccine vector consisted of an attenuated S. typhimurium strain engineered to express...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-4 (IL-4; BSF1); IL-4 receptor (CD124; IL-4RA); interleukin-13 (IL-13)

Gastrointestinal disease INDICATION: Pancreatitis In vitro and mouse studies suggest inhibiting IL-4 and IL-13 could help treat chronic pancreatitis. In pancreatic tissues from a mouse model of chronic pancreatitis or from patients with the disease, numbers of...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Pancreatitis Toll-like receptor 4 (TLR4) Mouse studies suggest CO-based therapeutics could help treat acute pancreatitis. In...
07:00 , Apr 14, 2008 |  BC Week In Review  |  Clinical News

Wetimicin: Phase II start

This year, Aida will begin a Chinese Phase II trial. Aida Pharmaceuticals Inc. (OTCBB: AIDA), Hangzhou, China   Product: Wetimicin   Business: Infectious   Molecular target: NA   Description: Broad spectrum amino-glycoside antibiotic   Indication: Treat infections   Endpoint: NA   Status:...
07:00 , Mar 31, 2008 |  BC Week In Review  |  Company News

Aida, Jiangsu Institute of Microbiology Co. Ltd. deal

Aida acquired Jiangsu for an undisclosed sum. Aida gets "several" undisclosed compounds that are in clinical trials in China. Aida markets Etimicin sulfate powder and infusion in China to treat inflammatory diseases such as acute...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Clinical News

Rh-Apo2L: Phase II started

The company began a Chinese Phase II trial in about 100 patients. Aida Pharmaceuticals Inc. (AIDA), Hangzhou, China   Product: Rh-Apo2L   Business: Cancer   Molecular target: Not available   Description: Broad spectrum genetic cell apoptosis agent   Indication:...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Clinical News

Rh-Apo2L: Phase II start

By year end, AIDA will begin a Chinese Phase II trial. Aida Pharmaceuticals Inc. ( AIDA), Hangzhou, China   Product: Rh-Apo2L   Business: Cancer   Molecular target: Not available   Description: Broad spectrum genetic cell apoptosis agent   Indication: Treat...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Clinical News

Rh-Apo2L: Phase III start

By year end, AIDA will begin a Chinese Phase III trial. Aida Pharmaceuticals Inc. ( AIDA), Hangzhou, China   Product: Rh-Apo2L   Business: Cancer   Molecular target: Not available   Description: Broad spectrum genetic cell apoptosis agent   Indication: Treat...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Company News

Aida, Shanghai Qiaer Bio-Technology Co. Ltd. deal

AIDA acquired a 33% stake in Qiaer for RMB27.8 million ($3.5 million) and now owns 78% of the company. AIDA Chairman and CEO Jin Biao will be chairman of Qiaer. Qiaer's lead product, Rh-Apo2L...